propranolol has been researched along with allopurinol in 37 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 10 (27.03) | 18.7374 |
| 1990's | 4 (10.81) | 18.2507 |
| 2000's | 9 (24.32) | 29.6817 |
| 2010's | 12 (32.43) | 24.3611 |
| 2020's | 2 (5.41) | 2.80 |
| Authors | Studies |
|---|---|
| Andrews, PR; Craik, DJ; Martin, JL | 1 |
| Topliss, JG; Yoshida, F | 1 |
| Gao, F; Lombardo, F; Shalaeva, MY; Tupper, KA | 1 |
| Gao, F; Lombardo, F; Obach, RS; Shalaeva, MY | 2 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Ahlin, G; Artursson, P; Bergström, CA; Gustavsson, L; Karlsson, J; Larsson, R; Matsson, P; Norinder, U; Pedersen, JM | 1 |
| Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Choi, SS; Contrera, JF; Hastings, KL; Kruhlak, NL; Sancilio, LF; Weaver, JL; Willard, JM | 1 |
| Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV | 1 |
| García-Mera, X; González-Díaz, H; Prado-Prado, FJ | 1 |
| Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ | 1 |
| Glen, RC; Lowe, R; Mitchell, JB | 1 |
| Ekins, S; Williams, AJ; Xu, JJ | 1 |
| Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V | 1 |
| Artursson, P; Haglund, U; Karlgren, M; Kimoto, E; Lai, Y; Norinder, U; Vildhede, A; Wisniewski, JR | 1 |
| Ambroso, JL; Ayrton, AD; Baines, IA; Bloomer, JC; Chen, L; Clarke, SE; Ellens, HM; Harrell, AW; Lovatt, CA; Reese, MJ; Sakatis, MZ; Taylor, MA; Yang, EY | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Jones, LH; Nadanaciva, S; Rana, P; Will, Y | 1 |
| Lillehei, RC; MacCarter, DJ; Shatney, CH | 1 |
| Christensen, LK; Hansen, JM | 1 |
| Dalipram, RA; Dusting, GJ; Sobey, CG; Woodman, OL | 1 |
| Jin, N; Packer, CS; Rhoades, RA | 1 |
| Hininger, I; Nordmann, R; Ribiere, C | 1 |
| Burghardt, B; Janero, DR; Lopez, R; Pittman, J | 1 |
| Günther, K; Modersohn, D; Pankau, H; Scheider, D; Tronicke, E; Uhlich, C; Urbaszek, W | 1 |
| Fleckenstein, L; Lasagna, L; Mazzullo, JM; Mundy, GR; Sundaresan, PR; Weintraub, M | 1 |
| Jameson, S | 1 |
| Iwaki, K; Yonetani, Y | 1 |
| Badawy, AA | 1 |
| Cybulska, I; Wasowska-Ciszek, T | 1 |
| Dalipram, RA; Sobey, CG; Woodman, OL | 1 |
| Abraham, E; Arcaroli, J; Shenkar, R | 1 |
| Earnest, R; Goodman, MD; McGlone, E; Morris, MC; Singer, KE; Stevens-Topie, S; Wallen, TE | 1 |
| Baucom, MR; Blakeman, TC; Goodman, MD; McGuire, JL; Schuster, RM; Singer, KE; Strilka, R; Wallen, TE; Youngs, J | 1 |
2 review(s) available for propranolol and allopurinol
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Drug interactions with oral sulphonylurea hypoglycaemic drugs.
Topics: Allopurinol; Analgesics; Anticoagulants; Chloramphenicol; Chlorpropamide; Disulfiram; Drug Interactions; Ethanol; Glyburide; Humans; Hypoglycemic Agents; Hypolipidemic Agents; Kinetics; Monoamine Oxidase Inhibitors; Novobiocin; Phenylbutazone; Phenytoin; Probenecid; Propranolol; Rifampin; Sulfonamides; Sulfonylurea Compounds; Tolbutamide | 1977 |
35 other study(ies) available for propranolol and allopurinol
| Article | Year |
|---|---|
Functional group contributions to drug-receptor interactions.
Topics: Animals; Calorimetry; Kinetics; Models, Biological; Protein Binding; Receptors, Cell Surface; Receptors, Drug; Structure-Activity Relationship | 1984 |
QSAR model for drug human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Humans; Models, Biological; Models, Molecular; Pharmaceutical Preparations; Pharmacokinetics; Structure-Activity Relationship | 2000 |
ElogD(oct): a tool for lipophilicity determination in drug discovery. 2. Basic and neutral compounds.
Topics: 1-Octanol; Chromatography, High Pressure Liquid; Pharmaceutical Preparations; Solubility; Water | 2001 |
Prediction of volume of distribution values in humans for neutral and basic drugs using physicochemical measurements and plasma protein binding data.
Topics: Blood Proteins; Chemical Phenomena; Chemistry, Physical; Half-Life; Humans; Hydrogen-Ion Concentration; Models, Biological; Pharmaceutical Preparations; Pharmacokinetics; Protein Binding | 2002 |
Prediction of human volume of distribution values for neutral and basic drugs. 2. Extended data set and leave-class-out statistics.
Topics: Algorithms; Blood Proteins; Half-Life; Humans; Hydrogen-Ion Concentration; Models, Biological; Pharmaceutical Preparations; Pharmacokinetics; Protein Binding; Statistics as Topic; Tissue Distribution | 2004 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Structural requirements for drug inhibition of the liver specific human organic cation transport protein 1.
Topics: Cell Line; Computer Simulation; Drug Design; Gene Expression Profiling; Humans; Hydrogen Bonding; Liver; Molecular Weight; Organic Cation Transporter 1; Pharmaceutical Preparations; Predictive Value of Tests; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Structure-Activity Relationship | 2008 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Topics: | 2008 |
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Topics: Administration, Oral; Biological Availability; Humans; Intestinal Absorption; Pharmaceutical Preparations | 2010 |
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
Topics: Antiparasitic Agents; Molecular Structure; Neural Networks, Computer; Parasitic Diseases; Quantitative Structure-Activity Relationship; Species Specificity; Thermodynamics | 2010 |
Developing structure-activity relationships for the prediction of hepatotoxicity.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Humans; Structure-Activity Relationship; Tetracyclines; Thiophenes | 2010 |
Predicting phospholipidosis using machine learning.
Topics: Animals; Artificial Intelligence; Databases, Factual; Drug Discovery; Humans; Lipidoses; Models, Biological; Phospholipids; Support Vector Machine | 2010 |
A predictive ligand-based Bayesian model for human drug-induced liver injury.
Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands | 2010 |
FDA-approved drug labeling for the study of drug-induced liver injury.
Topics: Animals; Benchmarking; Biomarkers, Pharmacological; Chemical and Drug Induced Liver Injury; Drug Design; Drug Labeling; Drug-Related Side Effects and Adverse Reactions; Humans; Pharmaceutical Preparations; Reproducibility of Results; United States; United States Food and Drug Administration | 2011 |
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
Topics: Atorvastatin; Biological Transport; Drug Interactions; Estradiol; Estrone; HEK293 Cells; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Least-Squares Analysis; Liver; Liver-Specific Organic Anion Transporter 1; Models, Molecular; Multivariate Analysis; Organic Anion Transporters; Organic Anion Transporters, Sodium-Independent; Protein Isoforms; Pyrroles; Solute Carrier Organic Anion Transporter Family Member 1B3; Structure-Activity Relationship; Transfection | 2012 |
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
Topics: Chemical and Drug Induced Liver Injury; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Decision Trees; Drug Evaluation, Preclinical; Drug-Related Side Effects and Adverse Reactions; Glutathione; Humans; Liver; Pharmaceutical Preparations; Protein Binding | 2012 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Development of a cell viability assay to assess drug metabolite structure-toxicity relationships.
Topics: Adenosine Triphosphate; Benzbromarone; Cell Line; Cell Survival; Chromans; Cytochrome P-450 CYP2C9; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Humans; Pharmaceutical Preparations; Thiazolidinediones; Troglitazone | 2016 |
Effects of allopurinol, propranolol and methylprednisolone on infarct size in experimental myocardial infarction.
Topics: Allopurinol; Animals; Blood; Coronary Disease; Disease Models, Animal; Dogs; Heart; Hemodynamics; Hydrogen-Ion Concentration; Methylprednisolone; Myocardial Infarction; Myocardium; Oxygen; Propranolol | 1976 |
Impaired endothelium-dependent relaxation of dog coronary arteries after myocardial ischaemia and reperfusion: prevention by amlodipine, propranolol and allopurinol.
Topics: Acetylcholine; Allopurinol; Amlodipine; Animals; Calcium Channel Blockers; Coronary Disease; Coronary Vessels; Dogs; Endothelium, Vascular; Female; In Vitro Techniques; Male; Muscle Relaxation; Muscle, Smooth, Vascular; Myocardial Reperfusion Injury; Nifedipine; Nitroglycerin; Propranolol | 1992 |
Reactive oxygen-mediated contraction in pulmonary arterial smooth muscle: cellular mechanisms.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Animals; In Vitro Techniques; Isoquinolines; Male; Muscle Contraction; Muscle, Smooth, Vascular; Norepinephrine; Oxygen; Phentolamine; Piperazines; Propranolol; Pulmonary Artery; Rats; Rats, Inbred Strains; Tetradecanoylphorbol Acetate; Verapamil; Xanthine Oxidase | 1991 |
Disturbances in myocardial creatine kinase following ethanol administration to rats--trials of prevention by allopurinol, desferrioxamine and propranolol.
Topics: Alcohol Drinking; Alcoholic Intoxication; Allopurinol; Animals; Creatine Kinase; Deferoxamine; Dose-Response Relationship, Drug; Ethanol; Male; Myocardial Contraction; Myocardium; Propranolol; Rats; Rats, Inbred Strains | 1991 |
Propranolol as xanthine oxidase inhibitor: implications for antioxidant activity.
Topics: Allopurinol; Animals; Binding, Competitive; Cell Membrane; Free Radicals; Iron; Lipid Peroxidation; Liposomes; Membrane Lipids; Myocardium; Oxidation-Reduction; Propranolol; Rats; Rats, Inbred Strains; Superoxides; Xanthine; Xanthine Oxidase; Xanthines | 1989 |
[Influence of metabolism-inhibiting as well as metabolism-accelerating and ionotropic drugs on myocardial survival time in the rat under anoxia conditions].
Topics: Adrenergic beta-Antagonists; Allopurinol; Animals; Carnitine; Cell Survival; Digitoxin; Female; Heart; Hypoxia; Male; Metaproterenol; Myocardium; Norepinephrine; Practolol; Prednisolone; Propranolol; Rats; Strophanthins; Theophylline; Thiamine Pyrophosphate | 1974 |
Current medical practice and the Food and Drug Administration. Some evidence for the existing gap.
Topics: Adult; Aged; Allopurinol; Angina Pectoris; Cephalexin; Child; Colchicine; Diuretics; Drug Labeling; Drug Prescriptions; Drug Therapy; Gout; Humans; Hypertension; Iron; Middle Aged; Physicians; Postoperative Complications; Propranolol; Retrospective Studies; United States; United States Food and Drug Administration; Uric Acid | 1974 |
[Effects of Inderal in the treatment of uremic hypertension].
Topics: Adult; Allopurinol; Diabetic Coma; Drug Combinations; Drug Interactions; Female; Humans; Hydralazine; Hypertension; Male; Middle Aged; Propranolol; Steroids; Uremia | 1971 |
Catecholamine-induced hyperuricemia in eviscerated rats with functional hepatectomy.
Topics: Animals; Catecholamines; Hepatectomy; Isoproterenol; Liver; Male; Propranolol; Rats; Rats, Inbred Strains; Uric Acid; Xanthine Oxidase | 1981 |
Possible involvement of the enhanced tryptophan pyrrolase activity in the corticosterone- and starvation-induced increases in concentrations of nicotinamide-adenine dinucleotides (phosphates) in rat liver.
Topics: Allopurinol; Animals; Corticosterone; Dactinomycin; Glucose; Liver; Male; NAD; NADP; Propranolol; Rats; Starvation; Stimulation, Chemical; Tryptophan; Tryptophan Oxygenase | 1981 |
[Treatment of arterial hypertension in old age].
Topics: Age Factors; Aged; Allopurinol; Antihypertensive Agents; Blood Pressure; Clonidine; Drug Therapy, Combination; Humans; Hydrochlorothiazide; Hypertension; Phthalazines; Propranolol | 1980 |
Allopurinol and amlodipine improve coronary vasodilatation after myocardial ischaemia and reperfusion in anaesthetized dogs.
Topics: Allopurinol; Amlodipine; Anesthetics; Animals; Dogs; Endothelium, Vascular; Female; Male; Myocardial Ischemia; Myocardial Reperfusion Injury; Propranolol; Vasodilator Agents | 1993 |
Activation of extracellular signal-regulated kinases, NF-kappa B, and cyclic adenosine 5'-monophosphate response element-binding protein in lung neutrophils occurs by differing mechanisms after hemorrhage or endotoxemia.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Animal Feed; Animals; Cyclic AMP Response Element-Binding Protein; Endotoxemia; Enzyme Activation; Hemorrhage; Injections, Intraperitoneal; Lung; Male; MAP Kinase Kinase 1; MAP Kinase Kinase 2; Mice; Mice, Inbred BALB C; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Mitogen-Activated Protein Kinase Kinases; Mitogen-Activated Protein Kinases; Neutrophil Activation; NF-kappa B; Phentolamine; Propranolol; Protein Serine-Threonine Kinases; Protein-Tyrosine Kinases; Tungsten; Xanthine Oxidase | 2001 |
Postinjury treatments to make early tactical aeromedical evacuation practical for the brain after TBI.
Topics: Adenosine; Air Ambulances; Allopurinol; Amitriptyline; Animals; Brain; Brain Chemistry; Brain Injuries, Traumatic; Cytokines; Disease Models, Animal; Emergency Medical Services; Lidocaine; Magnesium; Male; Mice; Mice, Inbred C57BL; Propranolol; Rotarod Performance Test | 2021 |
Postinjury Treatment to Mitigate the Effects of Aeromedical Evacuation After Traumatic Brain Injury in a Porcine Model.
Topics: Air Ambulances; Allopurinol; Animals; Brain Injuries, Traumatic; Humans; Interleukin-6; Mice; Propranolol; Saline Solution; Swine; Tranexamic Acid | 2022 |